Navigation Links
Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
Date:10/31/2007

WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will present a corporate overview at the 2007 Acumen BioFin Rodman & Renshaw Conference in New York.

The Company's presentation will take place at 8:50 a.m. (Eastern) on Tuesday, November 6, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through November 20, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the Company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the fourth quarter of 2007. For additional information, please visit the Company's website at

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...HARRISBURG, Pa., Nov. 21 /PRNewswire-USNewswire/ -...a, Governor Edward G. Rendell today remembered Li...ong teacher, an important partner in public servic...ylvania. , , "As the first woman elected li...ed public servant," said Governor Rendell. "Her fa...
(Date:11/21/2008)...But researchers remain cautious about future antib..., FRIDAY, Nov. 21 (HealthDay News) -- People with...disease (COPD) may be able to reduce the frequency... common antibiotic, a new report says. , The s... the American Journal of Respiratory and Critical...
(Date:11/21/2008)...MORGANTOWN, W.Va., Nov. 21 /PRNewswire-USNewswire/...examining whether a smokeless, spitless tobacco pr...e researchers have found that RJ Reynolds, Camel S...fy addiction - contains surprisingly high levels o...icotine than most other snuff products," said Bruc...
(Date:11/21/2008)...NEW YORK, Nov. 21 The general memb...ted to induct three new individuals at their Annua...he Pierre hotel in New York. A,Lifetime Achieveme...uctees into the Medical Advertising Hall of Fame a...g career with an account position,at Sudler &...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3
...rayers can help heart patients in the recovery pro...s at Duke // University Medical Centre. Researcher...apy showed a reduction death, heart failure, post-...an those without such therapies. 150 patients fro...
...ichard Greenberg and colleagues compared their Cel...cell culture with calf lymph derived vaccine. Smal... vaccine virus derived from calf lymph. This vacci...develop serious or life threatening adverse reacti...
...trontium ranelate for the treatment of osteoporosi... need careful interpretation. Nowadays the main tr...event bone breakdown. For patients with previous f...gent that enhances bone formation is preferable, a...
... recent research paper on chronic obstructive pulm...itation programs are often useful for patients of ...activities. Chronic obstructive pulmonary disease ...tricted airflow and conditions like lung tissue de...
Other Medicine News:Health News:The Benefits of Strontium in the treatment for Osteoporosis Questioned 2
(Date:11/20/2008)... 20 New Jersey American Water has... its customers in the following municipalities in ... Middlesex County , , , Dunellen ,...ay , South Plainfield , , , , ... , Bridgewater , Green Brook , ...
(Date:11/20/2008).... 20 Bionovo, Inc.,(Nas...esults from the Phase 1B,clinical trial of their ...,cancer, BZL101, at the Society for Integrative O...ta, Georgia. The Company,s oral presentation was ...esented as a part of the Best of the,SIO Session ...
(Date:11/20/2008)...ember 20 The Scandinavian-based dr...ced results of studies on its,lead antimicrobial ...n, DC,the studies showed that the novel lytic pe...ect, significantly better towards killing Staphylo...keted gold standard drugs. In,addition to this it...
(Date:11/19/2008).... 19 Biotech scientists increasing...y research to better understand the effects of nov...reports Genetic Engineering & Biotechnology N...guring out a new compound,s mechanism of action an...chnique, according to the November 15 issue of GE...
Breaking Medicine Technology:New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Yongye Biotechnology International Raises 249 4 Million in Private Placement 7603 1Yongye Biotechnology International Raises 249 4 Million in Private Placement 7603 2Yongye Biotechnology International Raises 249 4 Million in Private Placement 7603 3TOZAL 28R 29 Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3007 1TOZAL 28R 29 Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3007 2TOZAL 28R 29 Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3007 3Abuse of painkillers can predispose adolescents to lifelong addiction 4804 1Abuse of painkillers can predispose adolescents to lifelong addiction 4804 2A Better Tomorrow Treatment Center Inc Forterus Inc s Behavioral Healthcare Subsidiary is the First in the Nation to Offer DNA Customized Treatment 7600 1A Better Tomorrow Treatment Center Inc Forterus Inc s Behavioral Healthcare Subsidiary is the First in the Nation to Offer DNA Customized Treatment 7600 2
... & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, ...ical company focused on,the discovery and developm... today findings from its novel human-in-mouse (HIM...AVEO successfully created,invasive human tumors th...east tissue. This model enables scientists, for th...
...--(BUSINESS WIRE)--Apr 19, 2007 - Antares Pharma, ... recently completed,site application study demonst...ansdermal gel, was absorbed on a bioequivalent,bas...ent skin site,locations., The study was an open-la...site pharmacokinetic study. The trial enrolled 25,...
Other Medicine Technology:Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 2Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests.
For use with catalog #0454.
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests.
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests.
Medicine Products: